Research and development spending and technical efficiency: evidence from biotechnology and pharmaceutical sector by Grant, Kevin et al.
This is an Accepted Manuscript of an article published by Taylor & Francis Group in 





Research and Development Spending and Technical Efficiency: 
Evidence from Biotechnology and Pharmaceutical Sector  
 




Set within the expenditure context of the global financial crisis (GFC), this paper 
explores how the research and development (R&D) expenditures of biotechnology and 
pharmaceutical companies affect their technical efficiency levels. A balanced panel of 
149 U.S. firms operating in biotechnology and pharmaceutical sector (covering the 
period 2000–2017) was employed. Output-oriented partial frontier measures were used 
to measure the effect of R&D expenditure on firms’ technical efficiency levels.  
Findings suggest that company efficiency is an important contributor on the effects of 
R&D on productivity and efficiency. Result suggests that a relationship between 
technical efficiency and R&D expenditure exhibits a “U”-shape relationship. The 
estimated efficiency of biotechnology firms is higher compared to pharmaceutical firms 
driven by their higher R&D expenditure levels. We demonstrate that R&D expenditures 
are essential for firm efficiency.  We posit that a threshold level for achieving optimal 
efficiency levels exist, which can be used to inform managerial and policy-making 
decisions at the firm level. 
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The global financial crisis (GFC) has imposed unprecedented financial constraints on 
corporate spending across different business sectors (Campello et al., 2010). Coupled 
with the Dodd-Frank Act in the United States, the issue of return on innovation has 
never been so important. Yet, the following question remains: what is the most 
optimal point to investment in new technology, new products and services, etc.?   
 
Biotechnology and pharmaceutical (B&P) firms have historically been less exposed to 
the economic fluctuations of global economics due to their scale, share-gearing and 
historic success in the innovation cycle from research and development (R&D) 
investments (Mazzucato & Parris, 2014).  We contend that the ‘credit crunch’ from 
the outset of the GFC reduced available funding for B&P firms, which affected their 
ability to continue to develop, cultivate and maintain the same level of return from 
their innovation pipelines. This contention is informed by statistical analysis of a 
balanced panel (covering the period 2000–2017) of 149 U.S. biotechnology and 
pharmaceutical firms.   The period for this analysis captures the effect of R&D on the 
performance of companies before, during and after the GFC (Lee et al., 2015). We 
specifically targeted companies with a Standard & Poor’s Global Industry 
Classification Standard (GICS) equal to ‘35202010’ that operate United States. 
 
In addition to the lack of financial resources in R&D affected by the GFC the global 
pharmaceutical and biotechnology industry has been evolving in the last few decades 
(McKinsey 2017).  Patent expiries, weak new dug regime pipelines, regulatory 
changes, product withdrawals poorer R&D productivity, new payers and internet 
savvy beneficiaries (such as cancer and aids charities and campaign groups) have 
been pushing back on the cost of treatments, have and are challenging the 
development and sustainability of this market.  The need to ensure greater 
productivity may have forced B&P firms to hone their R&D activities.  What remains 
unclear - is there a tipping point for such investments and do the increases and 
decreases in R&D investment follow the same pattern of return? 
 
We acknowledge that innovation and its management has a much broader scope than 
just R&D expenditures or patents. Brand innovation is often perceived as being more 
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important than technical innovation in terms of its direct impact on growth and 
margins. It is difficult to measure such intangible results; therefore, we use R&D 
expenditures as a proxy for innovation activity and value. 
 
This paper advances the existing discussion on the role and place of R&D 
expenditures has within the GFC context of spending and returns at the corporate 
level. This research is needed at this time because the financial squeeze has prompted 
B&P firms to consolidate their activities. It is estimated that approximately 88,0001 
pharmaceutical employees, including scientists in R&D units were displaced between 
2009 and 2013 (Wang, 2014). This displacement equates to a 187% reduction in the 
workforce that engages in the ideation and invention stages of the innovation process. 
 
The B&P industry is connected to high levels of R&D activity, but given the credit 
squeeze is this still the case?  Understanding the nature of R&D efficiency and its 
elements is essential for designing R&D policies that effectively nurture innovation 
and promote technological progress.  We contend there may be a tipping point, were 
too much R&D activity hampers innovation. 
 
The B&P industry has also engaged in restructuring via mergers and acquisitions 
[M&As] (Wang, 2014). These changes were exclusively driven by the financial 
objective of firms to maintain or enhance profitability or scale up.  Booz and 
Company (2009), demonstrated that the Dow Jones U.S. Pharmaceutical Index fell by 
only 15%, compared to the Dow Jones Industrial Average of 38% between June 2008 
and March 2009. To combat this decline, the pharmaceutical industry has reduced 
costs over the last decade. Pharmaceutical companies have either cut costs on a stand-
alone basis or more aggressively through mergers or culture management of expense 
capital items (Wang, 2014). 
 
B&P firms allocate five times more investment to R&D relative to their sales than the 
average U.S. manufacturing firm because they want to or need to invest in their long-
term success via the innovation pipeline for new products and services. It has been 
observed that the productivity and efficiency of R&D in the B&P industry has 
                                                 
1 Source: Compiled by MHBK/IRD based on public company reports in Wang (2014). 
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declined (Scannell et al., 2012; Pammolli et al., 2011) or flat lined (Wang, 2014). 
Pfizer dramatically cut R&D spending from $11bn before their merger in 2009, 
($7.6bn from Pfizer and $3.4bn from Wyeth) to $6.55bn in 2013, which is even lower 
than Pfizer’s standalone R&D spending.2 
 
The productivity of R&D is measured by the number of new drugs that are approved 
and introduced to markets relative to R&D expenditures (Scannell et al. 2012). Many 
B&P companies have narrowed their business focuses and pooled their assets to 
create category leaders in an attempt to deliver short-term innovation gains. Scannell 
et al. (2012) estimate that the number of newly introduced drugs per billion U.S. 
dollars spent on R&D has halved every nine years since 1950. As Pammolli et al. 
(2011) clarify, this decline is the result of diminishing returns in the knowledge-
production function and a change in strategic direction, either to an innovation 
leadership strategy whereby the organisation focuses on scientific innovation or a 
focused niche strategy whereby non-traditional diseases are targeted. As such, R&D 
expenditures and intensities can be used as proxies for innovation. 
 
Changes in the management of commercial R&D, along with intensive pressure from 
shareholders to maximise short-term profits, have also decreased the probability of 
success across the industry from pursuing longer term research and development 
projects. Thus, commercial research by companies has focused on commercial 
success rather than grand societal challenges and sustainable innovation products 
(Zanders, 2011). 
 
Based on the above structural changes across the B&P sector, this paper advances the 
thinking on the role of R&D has in the biotechnology & pharmaceutical industry. It 
also builds upon the current conversations Delgado-Verde et al, 2016; Brem et al, 
2016) and in the Pharma sector Lowman (2012), while offering an alternative 
narrative and methodology. 
 
This paper differs from previous research on R&D in the B&P industry (e.g., 
Pammolli et al., 2011; Kessel, 2011; Scannell et al., 2012) as it assesses how the R&D 
                                                 
2 Compiled by MHBK/IRD based on data from Capital IQ sourced in Wang (2014). 
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expenditures of the companies affect their technical efficiency levels. The paper 
builds on the early work by Hossein Safizadeh and Murphy (1992) which provides the 
mechanism under which the R&D expenditure increases firms’ value creation through 
the generation of new product development. We further contribute to the study by Co 
and Chew (1997) in which they provide evidence that the R&D investment 
preferences are directly linked with manufacturing firms’ technical efficiency levels.  
 
This paper acknowledges that many firms have switched to more open innovation and 
co-creation eco-systems as illustrated by Lilly’s FIPNet strategy. This paper does not 
explore this trend, but rather explores the relationship between the productivity of the 
companies in terms of R&D expenditure and new products. We determine how these 
firms can improve production factors to maximise their value added. Numerous 
studies in different sectors and industries have used this type of analysis (e.g., Tsaur et 
al. 2017; Wang et al., 2015; Castellani & Pieri, 2013; O’Mahony & Vecchi, 2009; 
Chang & Chen, 2008) limited research on B&P firms exists (e.g., Hashimoto & 
Haneda, 2008; González & Gascón, 2004).  
 
Only a few studies explore the problem of productivity and efficiency in the B&P 
industry using company level data, and no studies have modelled in an efficiency 
framework, the direct effect between investment and value added. Hashimoto and 
Haneda (2008) analyse the efficiency of Japanese pharmaceutical companies, while 
González and Gascón (2004) analyse sources of growth in productivity in the Spanish 
pharmaceutical industry. Other studies (Pammolli et al., 2011; Kessel, 2011; Scannell 
et al., 2012) have used aggregated data in their analyses, but they do not provide the 
level of detail required, nor do they suggest any policy changes to managerial activity 
to maximise returns on innovation from technical efficiencies. 
 
Most studies establish statistical associations and provide no causal direction, any 
managerial policy discussion can only be indicative rather than directive, which is 
limiting.  
 
We posit an alternative methodological framework to estimate the efficiency of 
companies. We advance the current empirical research on efficiency and the 
productivity of R&D by applying a nonparametric framework that is based on 
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methodological developments regarding conditional efficiency measures. This enables 
the dynamic effects of R&D expenditures on the levels of production efficiency in a 
sample of 149 B&P companies between 2000 and 2017 to be captured. These sample 
companies were selected based on market performance via sales coupled with strong 
stakeholder and shareholder value for the period under investigation, using mean 
analysis. 
 
This approach is advantageous since contradictions exist in the limited amount of 
literature that exists, which is beset by differing methodological and practical 
considerations. The advantages of this approach are; first, the results in earlier studies 
may be contradictory because the a priori assumption concerning the functional form 
of the examined relationship could be erroneous when deploying parametric 
techniques. Second, the different methodological (econometric adopted) frameworks 
may be another potential source of conflicting results given the ideological premise. 
Third, the different datasets applied in the studies may cause ambiguity, particularly 
when involving differing periods and types of firms from different origins that 
operates in different markets. Fourth, the variables omitted from the empirical model, 
could affect the overall results and produce further inconclusive findings.  
 
To enrich the debate on how to measure and evaluate a firm’s performance and to 
offset earlier methodological issues, a new time-dependent conditional frontier model 
(Mastromarco & Simar, 2015) was utilised, following recent advances advocated by 
Bădin et al. (2012, 2014). In contrast to the traditional DEA approaches (Window 
Analysis or Malmquist Productivity Index), dealing with multiple time periods may 
be troublesome (Cooper et al., 2007).  Probabilistic DEA framework allows 
researchers and evaluators to capture the effect of R&D expenditure in a dynamic 
framework (time-dependent) that incorporates different periods and phenomena (e.g., 
the GFC) into performance measurement. 
 
Furthermore, any nonlinearity that may be present in the examined relationship 
without prior assumptions about the functional forms in terms of the estimated 
production function of the companies or the effects of R&D expenditures on their 




This paper provides the following intellectual contributions: 1) it unpacks the notion 
that it may be beneficial not to impose or adopt a separability assumption (Daraio et 
al., 2018), and 2) it assumes that the variables which influence firms’ production 
process (i.e., time and R&D expenditures) directly affect the shape of the estimated 
production frontier (i.e., the separability condition does not hold true). As a result, the 
obtained efficiency estimates are determined by the firms’ production inputs and 
outputs alongside with time and R&D expenditures (Simar and Wilson 2011). 
 
This paper is structured as follows: Section 2 provides a synthesis of the 
contemporary research on the productivity and efficiency of R&D. A summary of the 
most contemporary methodological approaches for assessing a firm’s efficiency is 
presented. Section 3 details the methodological framework used in this research, 
followed by a presentation of the findings and a discussion. Section 4 provides 
conclusions and proposes policy recommendations based on our analysis. 
  
2. Review of the related literature 
The concept of productivity is the expected indicator of efficiency in any production-
based system, yet various levels of analysis are used—individual, company, sector, 
and discipline, region, national and international data sets are often subjected to 
different interpretations. It is difficult to measure the total effects of the production 
factors. Whilst several parametric and non-parametric approaches have been used to 
handle the complexity associated with measuring productivity, each has limitations 
and benefits. Regardless of the method adopted, the correct identification of input and 
output indicators is critical for the reliability of results. Approaches that capture and 
measure productivity are constrained by and generally steeped in ideas that were 
created during the manufacturing era. 
 
This centrality of measuring efficiency is grounded in the mathematical and industrial 
era (‘what can easily be counted’).  However, we propose to offer a more neo-liberal 
approach, that focuses on evaluating ‘what really counts’. 
 
The following review is divided into two themes. First, we look at studies that deal 
with the excessive effects of R&D on productivity and growth in general terms. Then, 




Empirical studies have explored the links between R&D, total factor productivity 
(TFP) and economic growth across different industries (sectors), however, they tend 
to use aggregated data at the country or industry level to demonstrate this relationship. 
Individual company data is still not frequently or extensively used in such studies. 
One reason could be the restricted access to this type of data (Venturini, 2015), but 
also, that methodological protocols do not favour such data from being used. Early 
studies, such as Griliches and Lichtenberg (1984), Coven and Levinthal (1989) and 
Grossman and Helpman (1991) among others, recognise the importance of R&D as a 
key component of TFP. These links are well documented and often taken for granted 
in empirical studies (Mairesse & Sassenou, 1991; Hall & Mairesse, 1995) remain 
unchallenged, yet these studies, confirm the direct link between R&D and company 
productivity in the 1980s.  Building on the earlier work of Mairesse and Sasseneou 
(1991) who conducted a survey of econometric studies advocate that most of studies 
in the domain confirm a positive relationship between R&D and productivity. The 
work of Hall and Mairesse (1995) questions this comparability across studies in terms 
of defining the applied variables and estimation techniques correctly, especially given 
the different epistemological, methodological and practical research designs used in 
the studies. In addition, much of the work of ‘proving’ a direct link tends to see R&D 
and TEP as heterogeneous activities, even though they are often treated as 
homogeneous activities in the literature. 
  
It is often assumed that a positive and significant link exists between R&D and 
company productivity. It is interesting that this research thread tends to categorise 
each company into two categories: innovative and non-innovative firms. The often-
reported results confirm the hypothesis that the return on R&D is higher for more 
innovative companies, Griffith et al. (2004, 2006) extend this research on the 
traditional role of R&D as a stimulator for company innovation. 
 
We argue that by omitting the absorptive capacity of R&D provides biased results, 
suggesting that a new methodological approach should be posited, such as a network-
based DEA. The work of O’Mahony and Vecchi (2009) furthers this argument by 
highlighting the need to use both company accounts and industry data to make sense 
of the link between R&D spending, innovation and TFP. Their study combines R&D 
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and human capital to explore productivity in R&D in skill-intensive industries. 
Venturini (2015) enriches the conversation regarding the role of technology spill-
overs in productivity growth has.  At the firm level, R&D is an intentional activity 
and if this has positive effects on productivity via greater levels of efficiency as new 
product or new production mode deliver return. This is partly misguided, as they are 
likely to be upstream and downstream benefits from the innovation that may not be 
attributed to the innovation itself. 
 
In terms of a methodological protocol, most studies that focus on R&D and 
productivity are based on the estimation parametric function. While the Cobb-
Douglas production function is deployed in such studies, few studies in the 
biotechnology & pharmaceutical industry have used this function to directly 
investigate the productivity relationship with R&D investments. 
 
Pammolli et al. (2011) clarify the complexity of measuring the productivity of R&D 
in this industry. Pammolli et al. (2011) argue that the simple ratio of R&D 
expenditures to newly approved drugs does not reflect fully the changes in the B&P 
companies in terms of ‘dark innovation’. Dark innovation suggests that much 
innovation activity is hidden and goes unrecognised and unmeasured and may be 
negative, and that existing measures do not capture all forms of innovation within an 
organisation, such as managerial behaviours and values, due to well-intended 
researchers, being trapped in entrenched preconceptions and bias about how 
innovation works.  Pammolli et al. (2011) also show that the rate of introduction of 
new molecular entities has remained rather constant and attrition rates have risen. 
Pammolli et al. (2011) propose that other non-partisan measures are needed to 
estimate productivity by analysing trends in attrition rates and development times. 
Their work concludes that lower productivity can be explained by the low 
productivity of success.  
 
Scannell et al. (2012) also attempted to develop ‘new measures’ to identify the 
factor(s) that have caused the decline in pharmaceutical R&D efficiency. This study is 
significant because it provides an analytical framework that reveals how 
pharmaceutical companies approach productivity. Despite extensive research on 
company efficiency and productivity, there is limited ability to apply this research to 
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biotechnology & pharmaceutical companies, because a limited number of studies 
have considered R&D and its effects on company productivity in this industry. Using 
the Malmquist Productivity Index, González and Gascón (2004) conclude that 
technical efficiency improvements led to changes in productivity in the 
pharmaceutical industry, yet improvement and its associated growth were small.  
 
We identify four gaps in the current conversation:  
 
1) No studies have explored the quantitative side of R&D excess on return, which 
represents the optimal utilization of inputs in the production process in B&P firms. 
B&P companies are driven by profit maximisation (optimisation) for shareholder 
return and brand image, which determines the influx of R&D investment from 
investors (shareholders). Such an analysis would show and determine the optimal 
R&D expenditures for maximising company efficiency. 2) An analysis of the effects 
of the GFC on the efficiency of B&P firms and the use of R&D investment would 
provide policy information and inform strategic decisions. 3) Current methodological 
frameworks are based on the Cobb-Douglas production function even though linear 
programming techniques might be more appropriate when attempting to make sense 
of the relationship between technical innovations and sales turnover. 4) González and 
Gascón (2004) and Hashimoto and Haneda (2008) suggest a method of analysing 
productivity across companies; however, they do not directly include R&D in their 
model.  
 
3. Data and Methodology 
 
3.1 Variable description 
 
The sample consists of a balanced panel (covering the period 2000–2017) of 149 U.S. 
B&P firms (see Appendix 1 for company names), 97 of which operate in the 
biotechnology sector and 52 of which operate in the pharmaceutical sector.  
The period for this analysis captures the effect of R&D on the performance of 
companies before, during and after the GFC (Lee et al., 2015). The data was extracted 
from the Compustat database. We specifically targeted companies with a Standard & 
Poor’s Global Industry Classification Standard (GICS) equal to ‘35202010’ and 
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‘35201010’ that operate in the biotechnology and the pharmaceutical industries in the 
United States.  
 
Companies with complete records during the examined period and recorded R&D 
expenditures were included. As a result, the final data sample for the entire period 
consists of 2,682 observations. In order to measure the technical efficiency levels of 
the companies, we applied a production function framework that uses the number of 
employees (measured in thousands) and the value of property, plants and equipment 
(measured in thousands of U.S. dollars) as input factors. Moreover, we use the value 
added (measured in thousands of U.S. dollars) as companies’ production output 
whereas, the R&D expenditures (measured in thousands of U.S. dollars) are used as 
the factor that direct influence companies’ estimated technical efficiency levels.  
 
Table 1 presents diachronically the variables used in our analysis. The mean values 
presented in Table 1 indicate a decrease in R&D expenditures from 2008–2009, 
suggesting that the beginning of the GFC had a direct negative effect on this value. 
Figure 1a also presents the mean R&D expenditures (in logarithmic form) and their 
95% confidence intervals based on whether they operated in biotechnological or 
pharmaceutical sectors. The figures shows that companies operating in 
pharmaceutical had higher R&D expenditures. It was also noted that R&D 
expenditures decreased in both cases at the start of the GFC in 2008. Figure 1b 
presents the R&D intensity levels (R&D expenditures over company sales) for 
companies operating in biotechnological and those operating pharmaceutical sectors. 
It appears that the companies operating in biotechnological sector have higher R&D 
intensity than those operating in pharmaceutical sector. It is also evident that the R&D 
intensity of the companies decreased when the GFC started. This finding verifies the 
findings of Lee et al. (2015) who demonstrated the negative effect of the financial 
crisis on the innovation capacities of companies. 
 
Table 1 & Figure 1 about here 
 
3.2 Efficiency measurement 
Daraio and Simar (2005, 2006, 2007a, 2007b) examine the data-generating process 
(DGP) that characterises the production process of companies when different factors 
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are assumed to have a direct influence on the estimated process. Using this 
methodological framework, Bădin et al. (2012, 2014) further extend the analysis of 
the technical efficiency levels of companies with the presence of such factors both 
under full3 and robust (also called ‘partial’)4 frontiers. Mastromarco and Simar (2015) 
recently introduced the dynamic framework of these conditional efficiency measures. 
Based on those developments, we apply a time-dependent version of the conditional 
Order-m frontiers to examine the effects of R&D expenditures on the technical 
efficiency levels of companies. Let the production process of the companies be 
characterised as 
  ,  can produce x y x y  ,        (1) 
where 
pX R and 
qY R  denote the input and output vectors, respectively.  
Furthermore, let
dZ R  denote the vector of R&D expenditure that influence the 
production processes of the companies. Then, the conditional attainable set can be 
characterised as: 
  , ,   can produce z x y Z z x y   .                                                               (2) 
As Daraio and Simar (2005, 2006, 2007a, 2007b) suggest, the representation in (1) 
can be represented as: 
    ,, , 0 ,X Yx y H x y             (3) 
where    , , Prob ,X YH x y X x Y y   .                                                    (4) 
Then, by assuming the free disposability of inputs and outputs, the unconditional 
output oriented by Farrell (1957) and Debreu’s (1951) technical efficiency measure of 
a company operating at a point  ,x y  can be defined as: 
       , sup , sup 0Y Xx y x y S y x        ,     (5) 
where    ProbY XS y x Y y X x   , which is the conditional survival function of 
Y  given that X x . Then, by following Mastromarco and Simar (2015), we add 
time T as an additional conditional variable. For each period, t , the attainable set 
                                                 
3Several data envelopment analysis (DEA) papers apply full frontiers in order to investigate innovation 
and R&D efficiency problems (e.g., Groot and García-Valderrama, 2006; Wang and Huang, 2007; 
Hashimoto and Haneda, 2008). 
4According to Daraio and Simar (2007a), Order-m frontiers are more robust for outliers than for full 
frontiers. They also have the same rate of convergence of parametric estimators; therefore, the well-






  can be characterised from the support of the following conditional 
probability: 
    , , Prob , ,
t
X Y Z
H x y z X x Y y Z z T t     .      (6) 
Then, the time-dependent conditional output oriented by Farrell (1957) and Debreu’s 
(1951) technical efficiency measure of a company operating at  , Ztx y   can be 
defined as: 
       ,, sup , sup , 0Z tt t Y X Zx y z x y S y x z        ,    (7) 
where    , , Prob , ,
t
Y X Z
S y x z Y y X x Z z T t     . 
For our analysis, we follow Cazals et al. (2002) to apply the Order-m frontier, which 
is defined as the benchmark of the best practice among m companies drawn at random 
from a population of companies using fewer inputs than x . Let 𝑚 i.i.d. random 
variables , 1,...,iY i m  be generated according to the survival  Y XS y X x in order 
to define the random set as: 
    , , , 1,...,p qm ix x y R x x y Y i m       . Furthermore, the maximal output 
expansion can be characterised as: 
      , sup 0 ,m mx y x y x     ,        (8) 
and the Order-m output efficiency measure efficiency score is given from: 
    , ,m mx y x y X x    .        (9) 
Then, the Order-m efficiency score can be computed as: 





x y S uy X x du
     
  
.               (10) 
 
An Order-m efficiency score of less than one indicates a super-efficient level, 
whereas, efficiency scores equal to one suggest that the company lies on the frontier 
being efficient. Values greater than one indicate inefficiency (Cazals et al. 2002). If a 
company has a better performance compared to the 𝑚 randomly drawn companies 
with 𝑋 ≤ 𝑥 (in our case m is set to 20 companies)5, then it is said to be a super-
efficient company. In such circumstances companies’ Order-m levels are below unity. 
                                                 
5We follow Daraio and Simar (2005) and we chose a value of m companies (i.e. 20) under which the 




For instance and in the framework of our analysis, let us consider the case where a 
company is estimated of an Order-m output efficiency score equal to 1.6. Then we 
can say that this company would perform as efficient as the 𝑚 = 20 best benchmark 
companies with 𝑋 ≤ 𝑥 if its value added levels could increase by 60%. 
 
By following Mastromarco and Simar’s (2015) approach, the time-dependent 
conditional output-oriented Order-m efficiency scores can be computed as6: 
 
𝜆𝑚,𝑡(𝑥, 𝑦|𝑧) = ∫ [1 − (1 − 𝑆𝑌|𝑋,𝑍





.       (11) 
 
As indicated by Bădin et al. (2012, 2014), we can disentangle the effects of ‘R&D 
expenditure’ and ‘time’ from the efficiency levels of companies by considering the 
ratios of conditional to unconditional Order-m efficiency measures, which are the 
















 .              (12) 
We can investigate the ‘R&D expenditure’ and ‘time’ values that are associated with 
the companies by looking at the behaviours of the above ratios as a function of ‘R&D 
expenditure’ and ‘time’. For this purpose, we proceed by estimating the following 




R&D expenditure ,  Time
i tm i t it
R g u  ,           (13) 
where itu  indicates the usual error term. As suggested by Jeong et al. (2010), we 
apply a local linear estimator of the regression function that is less sensitive to the 
                                                 
quickly to the full frontiers estimates. According to Cazals et al. (2002), when 𝑚 → ∞ then the Order-
m efficiency scores converge to those derived from the Free Disposal Hull-FDH (Deprins et al., 1984) 
estimates. Finally, Bădin et al. (2012) suggest that when  𝑚 = 1 then the Order-m frontier measures a 
companies ‘average behaviour in terms of their technical efficiency levels. 
 
6 For computational issues and programming codes, see the works of Daraio and Simar (2005, 2006, 
2007a, 2007b) and Bădin et al. (2010, 2012, 2014). 
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edge effects.7 Then, for given input values, an increasing shape of mR  as a function of 
‘R&D expenditure’ and ‘time’ would correspond to the favourable effect of R&D and 
time on the efficiency levels of the companies. Meanwhile, a decreasing shape of 
R&D expenditure and time acting as undesirable outputs would signify a negative 
effect. 
 
4. Empirical Results 
 
Output-oriented partial frontier measures of Order-m to measure the technical 
efficiency levels of B&P companies were applied. Figure 2 presents the mean Order-
m technical efficiency levels of the companies. Given the fact that efficiency scores 
above unity indicate higher inefficiency levels, the results suggest that firms operating 
in the biotechnology sector perform better (i.e. efficiency scores < 1) compared to 
those operating in the pharmaceutical sector (i.e. efficiency scores > 1). Clearly all 
firms performed better during the initial years of our analysis. It is of note, higher 
fluctuations in their estimated efficiency levels occurred, especially after the initiation 
of GFC. Therefore, the exposure of these companies to the GFC is also reflected on 
the estimated technical efficiency levels. 
 
Figure 2 about here 
 
Figure 3 presents the density plots of the mean efficiency estimates for the companies 
over the examined period. The results are presented in overlapping three-year widow 
basis enable to assess companies’ performance before during and after the GFC 
period. In Figure 3 the vertical solid line indicates unity, whereas, the vertical dotted 
lines indicate the mean values. The density plots are presented in a three year basis 
(i.e. 2000-2002, 2002-2004, 2004-2006,…, 2014-2016 and 2016-2017) in order to 
evaluate diachronically companies’ distribution of their estimated  Order-m efficiency 
measures. The results signify that companies operating in the two evaluated sectors 
were having increased technical efficiency levels up to the initiation of GFC period 
(i.e. year 2007). This is evident on the subfigures 3a to 3d signified with the mass of 
                                                 
7 For the smoothing parameter (also called bandwidth) of the local linear estimation we have applied 




the distribution located to the left of the blue solid line (i.e. unity). However, during  
and after the period of GFC (i.e. subfigures 3e to 3i) companies are reported to have 
higher inefficiency levels indicated with the mass of their efficiency densities to be 
located to the right of the unity. As a result it is suggested that GFC had a negative 
impact on their estimated efficiency levels suggesting that companies were not able to 
fully recover and obtain similar technical efficiency levels as those obtained during 
the pre-crisis period (i.e., 2000–2007). 
 
Figure 3 about here 
 
Previously defined ratios from the unconditional and conditional Order-m estimates 
were used to examine the effects of R&D expenditures on the production processes of 
companies. As Daraio and Simar (2007a) suggest, partial frontiers produce robust 
estimators to deal with issues related to outliers and extreme values, which can mask 
the effect of the examined factors on the estimated production process.  
 
In our case,  , ,mR x y z t  as a function of R&D expenditure and time, provides 
information about the potential effects on companies’ estimated efficiency 
distributions.  
 
Figure 4 present’s three-dimensional illustrations of the examined effects for the 
sample (Figure 4a), the subsample of the firms that operate in biotechnology sector 
(Figure 4b) and for the subsample of firms that operate in pharmaceutical sector 
(Figure 4c). When examining the three-dimensional picture for the sample, it is of 
noteworthy interest to see that the relationships between time, R&D expenditures and 
technical efficiency is nonlinear. 
 
This nonlinear finding suggests the presence of increasing and decreasing returns, as 
indicated by the reported threshold value.  On further examination the effects of R&D 
expenditures on the efficiency levels of companies signifying a clear ‘U’-shaped 
relationship between the R&D expenditures of the companies and their technical 
efficiency levels can be seen. This indicates that when firms increase their R&D 
expenditure levels, this does not have a positive effect on their technical efficiency 
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levels. However, after a threshold value the effect becomes positive suggesting that 
increased R&D expenditures will result in an increase technical efficiency of 
companies.  
 
Figure 4b indicates the effect of time and R&D expenditures on the technical 
efficiency levels of firms operating in biotechnology sector. The three-dimensional 
picture presents again a ‘U’-shaped relationship between the R&D expenditures and 
technical efficiency of the companies. As previously this suggests a clear positive 
effect on efficiency levels for higher R&D expenditure, as signified by the increasing 
nonparametric regression line (after a threshold value). However, this effect becomes 
negative for lower R&D expenditures, thus suggesting the presence of diminishing 
returns. When examining the effect of time, the evidence suggests that there is a 
positive effect until the GFC began. However, the effect of time on the efficiency 
levels of the companies is negative after this point, which is indicated by a decreasing 
line. This finding supports the views of Lee et al. (2015) who suggest that the 
financial crisis had a negative effect on innovation-based firms. 
 
Figure 4c presents the effects of R&D expenditures and time on the technical 
efficiency levels of firms that operate only in pharmaceutical sector. The results 
indicate again a ‘U’-shaped relationship between R&D expenditures and the 
efficiency levels of the companies. The three-dimensional picture reveals that the 
effect is negative for lower R&D expenditures. Then after a certain threshold point the 
effect becomes positive for higher R&D expenditures levels. As for the time effect, it 
is evident that there is a nonlinear positive effect on firms’ estimated technical 
efficiency levels. 
 
The overall results signify an overall nonlinear relationship between time, R&D 
expenditures and the technical efficiency. It is evident that there is a ”U”-shape 
relationship among firms’ technical efficiency levels and their R&D expenditures.  
 






5. Conclusions and Implications 
 
The applied methodological framework adopted allowed the exploration of a link 
between R&D expenditures and the efficiency of companies. This research has 
demonstrated that a company efficiency is an important contributor to current R&D 
activity and that upstream spill overs on productivity and efficiency exist. The use of 
a balanced data set provides a better understanding of how biotechnology & 
pharmaceutical firms operate. In addition, current research on this sector has failed to 
analyse the behaviours of businesses during the GFC. 
 
The main results are as follows: pharmaceutical firms exhibit lower performance 
levels compared to the companies operating on the biotechnology sector.  
 
The data suggests that the GFC negatively affected the performance of companies that 
operate in the U.S. biotechnology and pharmaceutical sectors from 2008–2017. Thus, 
this research provides an important contribution by revealing how the volume of R&D 
expenditures affected the performance of companies during this period. 
 
It is also suggested that R&D expenditures have a ‘U’-shaped relationship with 
company performance. This result is confirmed for both types of firms (i.e., those that 
operate in biotechnology and pharmaceutical sectors). This is an important finding 
since it indicates that an optimal level of R&D exists.  This can also be seen when 
time is considered, as a ‘U’-shaped relationship is present.  
 
This study also provides some important policy recommendations for managers. It is 
proposed that R&D expenditures are essential for the efficiency of all B&P firms. 
However, a threshold for achieving optimal efficiency levels exist and managers need 
to be mindful to balance investment with return on investment or innovation. Firms 
must review their allocation of R&D expenditures in their production processes 
carefully.   
 
The results also propose that recent cuts in the numbers of employees have positively 
affected the efficiency of the companies examined in this research. However, these 
changes will only improve the fortunes of shareholders in the short term. Further 
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investigation is required to explore how these corporate changes will affect the 
development of new drugs and products as part of the innovation pipeline. This is 
because a high rate of return on R&D expenditure, as a proxy measure for innovation, 
no longer guarantees high yields. Thus, optimal R&D investment can yield a positive 
return, while the over-adoption of innovation can harm the efficiency of a firm.  
 
B&P companies will continue to compete vigorously, embrace new forms of 
innovation and introduce additional processes and financial innovations. They will 
also engage in patent disputes with generic brands, manage drug pipelines and 
leverage existing and new patents more effectively, while developing strategic 
alliances.  
 
This suggests that there may be room for further consolidation and international 
expansion through M&As for exploring new product innovations for diseases that are 
not yet on the radar to maximise revenue streams. M&As can improve two important 
aspects related to company efficiency: namely R&D expenditure and technical 
efficiency until the company ‘hits’ the threshold limit. 
 
B&P firms are likely to continue to engage in R&D, from chemical-based small 
molecules research to biology-based large molecules, such as antibodies and protein-
based innovations, as they are likely to always be undertaking R&D, but perhaps now 







Appendix 1: Names of the pharmaceutical companies examined in this study 
Biotechnological firms (97):  
ABEONA THERAPEUTICS INC, AGENUS INC, ALEXION 
PHARMACEUTICALS INC, ALKERMES PLC, AMAG PHARMACEUTICALS 
INC, AMARILLO BIOSCIENCES INC, AMARIN CORP, AMGEN INC, 
AMPLIPHI BIOSCIENCES CORP, ARENA PHARMACEUTICALS INC, 
ARQULE INC, ARROWHEAD PHARMACEUTICALS, AVID BIOSERVICES 
INC, BIOCRYST PHARMACEUTICALS INC, BIOGEN INC, BIOMARIN 
PHARMACEUTICAL INC, BIOSPECIFICS TECHNOLOGIES CP, BIOTIME 
INC, CALADRIUS BIOSCIENCES INC, CAPSTONE THERAPEUTICS CORP, 
CASI PHARMACEUTICALS INC, CELGENE CORP, CEL-SCI CORP, CELSION 
CORP, CTD HOLDINGS INC, CTI BIOPHARMA CORP, CURIS INC, CYTRX 
CORP, DIADEXUS INC, ENZON PHARMACEUTICALS INC , EXACT 
SCIENCES CORP, EXELIXIS INC, EXPEDEON AG, FIBROCELL SCIENCE 
INC, GENEREX BIOTECHNOLOGY CORP, GEOVAX LABS INC, GERON 
CORP, GILEAD SCIENCES INC, GT BIOPHARMA INC, HEMISPHERX 
BIOPHARMA INC, HERON THERAPEUTICS INC, IDERA 
PHARMACEUTICALS INC, IMMUCELL CORP, IMMUNOGEN INC, 
IMMUNOMEDICS INC, INCYTE CORP, INOVIO PHARMACEUTICALS INC, 
INSMED INC, IONIS PHARMACEUTICALS INC, ISORAY INC, ITUS CORP, 
KAZIA THERAPEUTICS LTD, KERYX BIOPHARMACEUTICALS INC, LA 
JOLLA PHARMACEUTICAL CO, LEXICON PHARMACEUTICALS INC, 
LIGAND PHARMACEUTICAL INC, MANHATTAN SCIENTIFICS INC, 
MATEON THERAPEUTICS INC, MYMETICS CORP, MYRIAD GENETICS INC, 
NAVIDEA BIOPHARMACEUTICALS, NEUROCRINE BIOSCIENCES INC, 
NORTHWEST BIOTHERAPEUTICS, NOVAVAX INC, NYMOX 
PHARMACEUTICAL CORP, ONCOVISTA INNOVATIVE THERAP, OPKO 
HEALTH INC, PALATIN TECHNOLOGIES INC, PDL BIOPHARMA INC, 
POLARITYTE INC, PRANA BIOTECHNOLOGY LTD, PROGENICS 
PHARMACEUTICAL INC, PROTALEX INC, PROTALIX BIOTHERAPEUTICS 
INC, REGENERON PHARMACEUTICALS, REGENERX 
BIOPHARMACEUTICALS, REPLIGEN CORP, RIGEL PHARMACEUTICALS 
INC, SANGAMO THERAPEUTICS INC, SAREPTA THERAPEUTICS INC, 
SEATTLE GENETICS INC, SHIRE PLC, SINOVAC BIOTECH LTD, SOLIGENIX 
INC, SPECTRUM PHARMACEUTICALS INC, STEMCELLS INC, TG 
THERAPEUTICS INC, TIKCRO TECHNOLOGIES LTD, UNITED 
THERAPEUTICS CORP, VERICEL CORP, VERNALIS PLC, VERTEX 
PHARMACEUTICALS INC, VG LIFE SCIENCES INC, VICAL INC, VITRO 
DIAGNOSTICS INC, WINDTREE THERAPEUTICS INC, XOMA CORP. 
 
Pharmaceutical firms (52): 
ACURA PHARMACEUTICALS INC, AEOLUS PHARMACEUTICALS INC, 
AKORN INC, ALLERGAN PLC, AOXING PHARMACEUTICAL CO INC, 
APRICUS BIOSCIENCES INC, ARADIGM CORP, ARALEZ 
PHARMACEUTICALS INC, ASSERTIO THERAPEUTICS INC, ASTRAZENECA 
PLC, AVADEL PHARMACEUTICALS –ADR, BAUSCH HEALTH COMPANIES 
INC, BAYER AG, BIODELIVERY SCIENCES INTL, BRISTOL-MYERS SQUIBB 
CO, CORCEPT THERAPEUTICS INC, DR REDDY'S LABORATORIES LTD, 
DURECT CORP, EISAI CO LTD, ELITE PHARMACEUTICALS INC , 
MISPHERE TECHNOLOGIES INC, ENDO INTERNATIONAL PLC, 
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GLAXOSMITHKLINE PLC, HEDGEPATH PHARMACEUTICALS, JOHNSON & 
JOHNSON, JUNIPER PHARMACEUTICALS INC, LANNETT CO INC, 
LESCARDEN INC, LILLY (ELI) & CO, MEDICINES CO, MERCK & CO, 
MYLAN NV, NEKTAR THERAPEUTICS, NOVARTIS AG, NOVO NORDISK 
A/S, PAIN THERAPEUTICS INC, PERRIGO CO PLC, PFIZER INC, PHIBRO 
ANIMAL HEALTH CORP, POLYDEX PHARMACEUTICALS LTD, PROPHASE 
LABS INC, PROVECTUS BIOPHARMACEUTICALS, RESPIRERX 
PHARMACEUTICALS, ROCHE HOLDING AG, ROCK CREEK 
PHARMACEUTICALS, SANOFI, SIGA TECHNOLOGIES INC, TARO 
PHARMACEUTICL INDS LTD, TELIGENT INC, TEVA PHARMACEUTICALS, 
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Table 1: Descriptive statistics of the variables 
 
  
    Property, Plant and Equipment Employees Value added Research and Development Expenditure 
2000 Mean 2310.208 5.693 3129.577 228.544 
 Std 7905.388 20.048 11311.287 726.271 
2001 Mean 2574.367 5.847 3332.884 256.329 
 Std 8735.214 20.435 12221.859 844.161 
2002 Mean 2978.619 6.123 3737.836 290.163 
 Std 9864.382 21.302 13581.434 914.772 
2003 Mean 3733.153 6.245 3921.525 368.702 
 Std 13550.284 21.662 13716.805 1335.326 
2004 Mean 4649.106 6.689 4443.344 431.046 
 Std 16630.107 22.440 15194.270 1446.351 
2005 Mean 4662.218 6.677 4626.441 408.757 
 Std 16413.541 22.028 15467.716 1308.770 
2006 Mean 5233.533 7.070 5140.204 503.806 
 Std 17774.340 22.966 16839.482 1499.914 
2007 Mean 5840.323 7.054 5688.741 565.848 
 Std 19095.256 22.624 18512.966 1651.542 
2008 Mean 5900.110 7.027 5778.426 591.596 
 Std 18988.941 22.373 18413.830 1743.657 
2009 Mean 7543.673 7.586 6128.878 556.114 
 Std 26522.827 24.284 19296.649 1685.112 
2010 Mean 7733.551 7.652 6833.036 634.610 
 Std 26175.661 24.341 21530.030 1979.026 
2011 Mean 8066.947 7.847 7115.086 621.680 
 Std 26576.221 24.630 22086.838 1865.955 
2012 Mean 8457.296 7.935 7193.504 646.668 
 Std 27206.962 24.660 21980.821 1909.470 
2013 Mean 8817.582 8.023 7386.796 660.933 
 Std 27298.997 24.676 22209.733 1895.441 
2014 Mean 9228.462 8.188 7310.369 682.475 
 Std 27084.319 24.815 21142.961 1873.023 
2015 Mean 10589.943 8.524 7396.565 723.216 
 Std 29430.312 24.930 20638.986 1893.273 
2016 Mean 11333.438 8.596 7625.388 783.074 
 Std 30537.949 24.699 20811.788 2057.719 
2017 Mean 11503.735 8.494 8013.522 857.062 





























Figure 3: Estimated density plots of companies Order-m efficiency scores based on 
three-year overlapping widows. 
 










Figure 4: The effect of time and R&D expenditure on companies’ performance 
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